×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

CLL

Amy Paturel
In what was once an incurable cancer — chronic lymphocytic leukemia — scientists are seeing remissions that could last for decades.
Jessica Skarzynski
Here are the top 5 CURE stories for July 2019.
Kristie L. Kahl
With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.
Jessica Skarzynski
The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.
Katie Kosko
Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.

 
Kristie L. Kahl
The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.
Katie Kosko
Patients with chronic lymphocytic leukemia have newer options that include targeted therapy combinations and CAR-T cell therapy.
OncLive Staff
The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Beth Fand Incollingo
Christopher Harington Dwyer, founder of CLL Canada and online chat contributor, leaves a legacy of support and knowledge.
 
Kristie L. Kahl
The Bruton tyrosine kinase inhibitor showed a statistically-significant and clinically-meaningful improvement in progression-free survival in patients with previously-treated CLL.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×